New York City
About Dante LabsDante Labs is an international NGS-based biotech company with offices in Europe and the United States. Please use the form below to inquire about our tests, research grant opportunities and potential partnerships.
CEO: Andrea Riposati
Please click here for Dante Labs' products.
29 articles with Dante Labs
Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery
Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases.
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
Mainz Biomed N.V. announced a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates.
Dante Labs receives grant by Italian government to pilot revolutionary CE-IVD, clinical whole genome sequencing-based Citizen Test for a G7 country, starting a new era in clinical genomics
Dante Labs , a global leader in genomics and precision medicine, is pleased to announce the Italian Ministry of Economic Development has selected Dante to develop and pilot the first fully-CE-IVD, clinically approved whole genome sequencing (WGS) test for the citizens of Italy to be named the Dante Citizen Test.
Dante Labs selected to provide genetic testing for Abu Dhabi Stem Cells Center, jointly developing mRNA cancer vaccines
Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the company has been selected as the genetic testing provider for Abu Dhabi Stem Cells Center, the Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine.
Dante Labs announces ventures into biosimulation and drug discovery, demonstrating the predictive value of the Dante Platform
Dante Labs , a global leader in genomic information and precision medicine, announces new genomic driven biosimulation and significant progress made to its drug discovery program, demonstrating the value of the Dante Platform.
Dante Labs establishes the first of its Regional Medical Genomics Boards in Europe made of national and multinational world leaders in genomics
Dante Labs announces the establishment of the first of its Medical Genomics Boards, strengthening the Company’s mission and research activity in this new frontier of healthcare, using genomics to promote prevention and treatment.
Dante Labs unveils Dante Genomics, the Company’s B2B global online marketplace delivering genomic solutions for medical professionals, researchers and pharma
Dante Labs today announced the launch of Dante Genomics, an online marketplace portal specifically dedicated to healthcare providers, clinics, researchers and governments which will offer advanced genomic services for research and clinical applications.
Dante Labs announces expansion of its Whole Genome Sequencing test with enhanced and broader offering
Dante Labs today announced the expansion of its Dante 30X Whole Genome Sequencing Test with personalized interpretation leveraging Dante’s proprietary Extensa Software Platform.
Dante Labs Partnering with The Renato Dulbecco Foundation to advance personalized medicines for cancer, COVID-19 and rare diseases
Dante Labs today announced it has partnered with The Renato Dulbecco Foundation to deliver more personalized therapies in rare diseases, oncology and COVID-19.
Dante Labs Announces Worldwide Universal Access to Whole Genome Sequencing with 50% Off Black Friday Offering
Dante Labs today announced its Black Friday offer for whole genome sequencing test and interpretation at 50% off its already unbeatable list price, plus free worldwide shipping.
Dante Labs, a global leader in genomics and precision medicine, is pleased to announce its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference.
Dante Labs Announces Appointment of Global Legal Expert Rachel Haverfield as General Counsel to its Expanding Leadership Team
Dante Labs today announced the appointment of Rachel Haverfield to the company’s leadership as General Counsel to drive the growth and scale of the business and opportunity.
Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director
Dante Labs today announced the appointments of Andre Nel, Dalila Rahmani, Laura D’Angelo and Omar Elbakshish to the company’s management team, expanding its global leadership to help scale the growing business.
9/3/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Dante Labs Announces Appointment of Sandra Close to its Board of Directors to Support Strategic Initiatives in Diagnostics
Dante Labs announced today the appointment of Sandra Close, Ph.D., as a member of its Board of Directors.
Dante Labs Announces Appointment of Mark Van Oene to its Board of Directors to Support Operational Approach and Commercial Strategy
Dante Labs announced today the appointment of Mark Van Oene as a member of its Board of Directors.
Dante Labs Announces Appointment of Healthcare Veteran and GRAIL SVP Mark Morgan to Board Of Directors to Support Genomic and Precision Medicine Scaling in the United States
Dante Labs announced today the appointment of Mark Morgan as a board member.
Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy
Dante Labs, a global leader in genomics and precision medicine, announced the appointment of Bob Ragusa as a board member.
Dante Labs commits to ending Rare Disease Odysseys globally through Stripe2be: a patient-centric whole genome based solution tailored for rare disease patients
Dante Labs announced the launch of Stripe2be, a platform and business unit fully dedicated to rare disease patients, offering personalized, AI-driven reports based on Whole Genome Sequencing and leveraging Dante Labs’ CE-IVD, ISO13485 certified Immensa Genomic Interpretation Software.
Dante Labs, a leading genomics and diagnostics company, announced the acquisition of Cambridge Cancer Genomics, a groundbreaking Y-Combinator company & leader in machine learning for clinical oncology, to create a single platform with unparalleled capabilities in genomics and oncology data analysis.